健脾通络解毒法对胃癌前病变患者NF-κB细胞凋亡通路影响的研究

Research of Jianpi Tongluo Jiedu Therapy on NF-κB Apoptotic Pathway for PLGC Patients

目的:观察健脾通络解毒法干预胃癌前病变(PLGC)的临床疗效;探讨健脾通络解毒法对PLGC的作用机制,揭示健脾通络解毒法可能通过调控NF-κB蛋白靶点对PLGC细胞凋亡产生影响,从而发挥其临床疗效。方法:对依据临床诊断及纳入标准入组的36例PLGC患者,予健脾通络解毒方干预治疗6个月,采集治疗前后症状变化及内镜下表现,应用免疫组化SP法检测治疗前后活体组织中NF-κB的表达,TNNEL法染色检测凋亡指标的改变。结果:本研究表明,患者经健脾通络解毒法治疗后,胃镜下病变程度较疗前明显减轻,肠化、不典型增生的差异具有统计学意义(P<0.01);同时,治疗前后病理组织中NF-κB阳性表达率下降(P<0.05),其凋亡指数疗后较前下降,但经统计学分析无显著性差异(P>0.05)。

Objective ：To observe the clinical effectiveness of Jianpi Tongluo Jiedu therapy on patients with PLGC and explore the mechanism to show the impact on apoptosis through the regulation of NF - -κB protein targets and its clinical efficacy. Methoas ：36 patients of PLGC based on clinical diagnosis and inclusion criteria were given 6 months treatment by Jianpi Tongluo Jiedu therapy. Changes in symptoms before and after treatment and endoscopic features were collected. NF - -κB from living tissue expression was detected by Immunohistochemieal SP method as well as changes in apoptotic index by TNNEL staining method. Results：This study showed that patients＇endoscopic lesions was significantly reduced compared with those before treatment. Intestinal metaplasia and dysplasia difference was statistically significant（ P 〈 0. 01 ）. Meanwhile, expression rate of NF - -κB was decreased （P 〈 0. 05 ）. Its apoptotic index was decreased after treatment, but there was no statistical significant difference （P 〉 0. 05 ）.